This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Buyside Predictions for 2012

Stocks in this article: GILD DNDN REGN VRTX ONTY YMI CELG

Some other predictions from Schoenebaum's survey:

An average of 37% of respondents believe Vertex's "combo trial" cystic fibrosis will yield unambiguously positive results.

Just 29% of investors believe FDA will approve Onyx Pharma's (ONXX) multiple myeloma drug carfilzomib based on phase II data.

Celgene gets a vote of confidence with 65% of respondents believing European regulators grant full approval to Revlimid as a front-line therapy for multiple myeloma.

Gilead's (Pharmasset) PSI-7977 will yield a "cure rate" of 72% when results of a phase II study are announced this spring.

Biggest upside surprises for 2012:
"JNJ acquires VRTX"
"Stimuvax actually works in Phase III"
"Mark will stop sending out surveys like this one!!"
"ANTH Lupus works - monthly injection, making long term oppo for benlysta small"
"Solaneuzimab fails miserably (no surprise), but bapineuzumab works well enough to have a legit shot at approval based on subgroup efficacy."
"Celgene's Phase III Abraxane+Gemcitabine in metastatic pancreatic is stopped early due to highly statistically significant OS benefit versus gemcitabine and becomes standard of care (already covered by NCCN guidelines based on Phase II)"
"YMI takeout"
"Targacept has a positive trial"
""VVUS gets Qnexa approved post panel meeting"

Biggest downside surprises for 2012:
"People will realize that ALXN has no patent protection beyond 2017 in EU and ROW and that the enobia acquisition will show their desperation to acquire around that."
"Continued lack of robust M&A"
"YMI - based on its ASH poster in Dec' 11 on its myelofibrosis drug CYT387, YMI has raised hopes of being able to treat anemia in sickle cell disease and thalassemia patients. These hopes will be dashed in '12."
"INHX trials halted for safety"
"Vertex combination CF data fails to impress"
"Bg12 trial patient gets PML"
"MNTA - a short"
"TIE: ONTY misses survival endpoint in Ph3 lung cancer trial and VVUS has to do a large CV outcomes trial a la OREX."
"The Mayans were right..."
"EU dings CELG"
"New ceo at AMGN will be same dud as Kevin Sharer "
"Regeneron's Eylea will be a total wash-out Human Genome and Dendreon both file for bankruptcy"
"Pharmasset / Gilead (VRUS / GILD) PSI-7977 fails to achieve SVR of 80%, leaving all US sell-side analysts with their pants down and GILD share tumbling."

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs